The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000850370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/06/2026
Date registered
Help: Date registered
13/07/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The effects of a curcumin extract on cognition, mood, fatigue, sleep, and menopausal symptoms in peri- and postmenopausal women: a randomised, double-blind, placebo-controlled trial
Scientific title
The effects of a curcumin extract (Curcugen) on cognition, mood, fatigue, sleep, and menopausal symptoms in peri- and postmenopausal women: a randomised, double-blind, placebo-controlled trial
Additional trial identifiers [1] 314618 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cognition 342567 0
Mood fluctuations 342568 0
Fatigue 342569 0
Sleep disturbance 342570 0
Menopausal symptoms 342571 0
Condition category
Condition code
Neurological 338720 338720 0 0
Other neurological disorders
Mental Health 338721 338721 0 0
Other mental health disorders
Alternative and Complementary Medicine 338722 338722 0 0
Herbal remedies
Reproductive Health and Childbirth 338723 338723 0 0
Menstruation and menopause
Metabolic and Endocrine 338856 338856 0 0
Other endocrine disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Curcumin extract (Curcugen) (1 capsule taken orally, twice daily, in the morning and evening, with food, delivering 800 mg a day for 12 weeks). Adherence to capsule intake will be measured by a count of capsules returned at week 12.
Intervention code [1] 334544 0
Treatment: Other
Description of the comparator or control
A matching placebo (containing cellulose) in terms of taste and appearance, and containing all ingredients except the active ingredient (curcumin). 1 cellulose capsule taken orally, once daily after breakfast for 12 weeks. Adherence to capsule intake will be measured by a count of capsules returned at week 12.
Control group
Placebo

Outcomes
Primary outcome [1] 345932 0
Cognitive Performance
Timepoint [1] 345932 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [1] 463805 0
Working memory
Timepoint [1] 463805 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [2] 463806 0
Attention
Timepoint [2] 463806 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [3] 463807 0
Processing speed
Timepoint [3] 463807 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [4] 463810 0
Episodic memory
Timepoint [4] 463810 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [5] 463811 0
Menopausal symptoms
Timepoint [5] 463811 0
Day 0 (the day before commencement of intervention), week 4, 8, and 12 post-intervention commencement
Secondary outcome [6] 463812 0
Depressive symptoms
Timepoint [6] 463812 0
Day 0 (the day before commencement of intervention), week 4, 8 and 12 post-intervention commencement
Secondary outcome [7] 463813 0
Anxiety Symptoms
Timepoint [7] 463813 0
Day 0 (the day before commencement of intervention), week 4, 8 and 12 post-intervention commencement
Secondary outcome [8] 463814 0
Sleep disturbance
Timepoint [8] 463814 0
Day 0 (the day before commencement of intervention), week 4, 8 and 12 post-intervention commencement
Secondary outcome [9] 463815 0
Fatigue
Timepoint [9] 463815 0
Day 0 (the day before commencement of intervention), week 4, 8 and 12 post-intervention commencement
Secondary outcome [10] 463816 0
Pain
Timepoint [10] 463816 0
Day 0 (the day before commencement of intervention), week 4, 8 and 12 post-intervention commencement
Secondary outcome [11] 463817 0
Brain fog
Timepoint [11] 463817 0
Day 0 (the day before commencement of intervention), week 4, 8 and 12 post-intervention commencement
Secondary outcome [12] 463818 0
Interleukin-6
Timepoint [12] 463818 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [13] 463819 0
Tumour necrosis factor alpha
Timepoint [13] 463819 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [14] 463820 0
Leptin
Timepoint [14] 463820 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [15] 463821 0
Ghrelin
Timepoint [15] 463821 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement
Secondary outcome [16] 463822 0
Fasting glucose
Timepoint [16] 463822 0
Day 0 (the day before commencement of intervention) and week 12 post-intervention commencement

Eligibility
Key inclusion criteria
1. Women aged 40 to 65 years
2. Women with an intact uterus and at least one ovary.
3. Perimenopausal or early postmenopausal, defined as:
a. menstrual-cycle changes persisting for at least 3 months, including a persistent change in cycle length, frequency, or episodes of menstrual skipping consistent with the menopausal transition; or
b. no menstrual period for at least 12 consecutive months.
4. For postmenopausal participants, the final menstrual period occurred no more than 6 years before screening.
5. Women using menopausal hormone therapy must have been taking the same formulation, dose, and route for at least 12 weeks before baseline, must not anticipate changing treatment during the study, and must have sufficient menstrual and clinical history to allow reliable classification as perimenopausal or early postmenopausal.
6. Self-reported difficulties with memory, concentration, attention, word-finding, or clear thinking that:
a. are rated at least 4 on a 0–10 severity scale;
b. have been present during most weeks over the previous 3 months;
c. began or became noticeably worse during the menopausal transition; and
d. cause at least mild interference with daily functioning, defined as a score of at least 2 on a 0–10 interference scale.
7. BMI between 18 and 35 kg/m2
8. No planned commencement of a treatment likely to materially affect cognitive function, menopausal symptoms, mood, sleep, inflammation, or study safety during the study period.
9. Understand, willing and able to comply with all study procedures.
10. Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the trial.
Minimum age
40 Years
Maximum age
65 Years
Sex
Females
Healthy volunteers
No
Key exclusion criteria
1. Menstrual changes that are considered primarily attributable to pregnancy, a medical condition, or another cause unrelated to the menopausal transition.
2. Current use of hormonal contraception that prevents a reliable classification of the menopausal stage. Stable menopausal hormone therapy is permitted in accordance with the inclusion criteria.
3. A recently diagnosed or inadequately managed medical condition that, in the Investigator’s judgement, may affect participant safety, study participation, or interpretation of the outcomes, including but not limited to diabetes, hypertension, cardiovascular disease, gastrointestinal disease, biliary disease, autoimmune disease, endocrine disease, or a chronic or acute pain condition.
4. A current neurological or psychiatric disorder that, in the Investigator’s judgement, is likely to materially affect cognitive performance, participant safety, or adherence to study procedures, including but not limited to dementia, Parkinson’s disease, psychotic disorders, bipolar disorder, or significant head injury, other than stable mild-to-moderate depression or anxiety.
5. Use of a supplement containing curcumin or turmeric within the previous 8 weeks.
6. Regular ongoing use of medications considered likely to materially affect cognitive performance, mood, sleep, menopausal symptoms, inflammation, or the safety or metabolism of the investigational product, including benzodiazepines, anticholinergics, antipsychotics, and regular anti-inflammatory medication. Occasional analgesic use may be permitted at the Investigator’s discretion if the dose and pattern of use are stable.
7. Commencement of, or change in, a pharmaceutical medication likely to affect cognitive function, menopausal symptoms, mood, or sleep within the previous 8 weeks, or an anticipated change during the study period.
8. Commencement of, or change in, a nutritional or herbal supplement likely to affect cognitive function, menopausal symptoms, mood, or sleep within the previous 4 weeks, or an anticipated change during the study period.
9. A planned major lifestyle or dietary change during the study period.
10. Alcohol intake greater than 14 standard drinks per week.
11. Current regular illicit drug use or a history of regular illicit drug use within the previous 12 months.
12. Current smoking or regular use of nicotine-containing products, defined as use on at least one day per week within the previous 3 months.
13. Pregnancy, breastfeeding, or intention to become pregnant during the study period.
14. Significant surgery within the previous 6 months that affects general health or daily functioning, or planned surgery during the study period.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Numbered opaque cartons
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 319178 0
Commercial sector/Industry
Name [1] 319178 0
Dolcas Biotech LLC
Country [1] 319178 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Clinical Research Australia
Address
Country
Australia
Secondary sponsor category [1] 325163 0
None
Name [1] 325163 0
Address [1] 325163 0
Country [1] 325163 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 317762 0
National Institute of Integrative Medicine Human Research Ethics Committee
Ethics committee address [1] 317762 0
Ethics committee country [1] 317762 0
Australia
Date submitted for ethics approval [1] 317762 0
10/03/2026
Approval date [1] 317762 0
28/04/2026
Ethics approval number [1] 317762 0
0166_2026

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 142054 0
Dr Adrian Lopresti
Address 142054 0
Clinical Research Australia, 38 Arnisdale Road Duncraig WA 6023
Country 142054 0
Australia
Phone 142054 0
+61 8 94487376
Fax 142054 0
Email 142054 0
Contact person for public queries
Name 142055 0
Adrian Lopresti
Address 142055 0
Clinical Research Australia, 38 Arnisdale Road Duncraig WA 6023
Country 142055 0
Australia
Phone 142055 0
+61 8 94487376
Fax 142055 0
Email 142055 0
Contact person for scientific queries
Name 142056 0
Adrian Lopresti
Address 142056 0
Clinical Research Australia, 38 Arnisdale Road Duncraig WA 6023
Country 142056 0
Australia
Phone 142056 0
+61 8 94487376
Fax 142056 0
Email 142056 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Access subject to approvals by Principal Investigator ([email protected])

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.